Possibilities of using melatonin in gynecology

Authors

DOI:

https://doi.org/10.18370/2309-4117.2017.34.96-101

Keywords:

melatonin, menopausal disorders, premenstrual syndrome, dysphoria, sleep disorders, ovulation

Abstract

For the modern gynecologist, the problem of human aging acquires a special urgency – the tasks of preserving the reproductive potential of a woman, alleviating the symptoms of perimenopause come to the fore. Clinical manifestations of climacteric syndrome are very diverse and polysymptomatic and can vary from the presence of several symptoms to the development of the entire symptom complex. In the article the modern strategies of conducting women during menopausal transition and postmenopause are considered: hormone replacement therapy as the main method of correction and prevention of climacteric disorders, as well as auxiliary methods – phytoestrogens, anticonvulsants, antidepressants, agents acting on the autonomic nervous system, multivitamin complexes, plant extracts that are used more or less successfully in clinical practice.

Melatonin preparations, analogues of one of the main endogenous adaptogens, are of particular interest in this series. This review describes the main effects of melatonin, its place in the complex treatment of the proliferative processes of the reproductive system, in particular, in the treatment of premenstrual syndrome, dysphoria, correction of sleep disorders in the perimenopause, its special role in the maturation of the follicle and ovulation. Melatonin is a universal natural adaptogen with a sleep effect, which is recommended by the National Consensus on the management of patients in menopause as a preparation of additional non-hormonal therapy. In the treatment of climacteric syndrome, it can be used at a dose of 1.5 mg 30 minutes before sleep for three months. It can be recommended as a monotherapy in the mild course of menopause and the prevalence of sleep disorders. If symptoms are more pronounced, melatonin should be combined with hormone replacement therapy.

Synthetic analogue of melatonin is represented in Ukraine by drug Vita-Melatonin produced by PJSC “Kiev Vitamin Plant”. The drug allows to perform the task of increasing the effectiveness of therapy for various gynecological diseases. Not being selectively tropic to the reproductive system, melatonin promotes adaptation, improvement of the general condition and well-being of women in the climacteric period.

Author Biographies

Н. В. Яроцкая, State Institution “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”

Junior researcher at the Endocrine Gynecology Department

Е. В. Занько, State Institution “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”

Postgraduate student at the Endocrine Gynecology Department,

References

  1. Clinical recommendations. Obstetrics and gynecology. Issue 2. / Ed. by V.I. Kulakov. Moscow. GEOTAR-Media (2008).
  2. Genazzani, A.R., Gambacciani, M., Simoncini, T. “Menopause and aging, quality of life and sexuality.” Climacteric 10.2 (2007): 88–96.
  3. Nelson, H.D., Haney, E., Humphrey, L., et al. “Management of menopause-related symptoms.” Evid Rep Technol Assess (Summ) 120 (2005): 1–6.
  4. Smetnik, V.P., Illina, L.M. “The role of sex hormones in the development of metabolic disorders in women in peri- and early postmenopausal women.” Climaktery 1 (2009): 8–13.
  5. North American Menopause Society. “Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.” Menopause 11 (2004): 11–33.
  6. Col, N.F., Guthrie, J.R., Politi, M., Dennerstein, L. “Duration of vasomotor symptoms in middle-aged women: a longitudinal study.” Menopause 16 (2009): 453–7.
  7. Politi, M.C., Schleinitz, M.D., Col, N.F. “Revisting the duration of vasomotor symptoms of menopause: a meta-analysis.” J Gen Intern Med 23 (2008): 1507–13.
  8. Freeman, E.W., Sammel, M.D., Lin, H., et al. “Duration of menopausal hot flushes and associated risk factors.” Obstet Gynecol 11.5 (2011):1095–104.
  9. Hodis, H.N., Mack, W.J. “Postmenopausal hormone therapy in clinical perspective.” Menopause 14.5 (2007): 944–57.
  10. Sturdee, D.W., et al. “Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health.” Climacteric 14 (2011): 302–20.
  11. Gompel, A., Rozenberg, S., Barlow, D.H. “The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy.” Maturitas 61 (2008): 227–32.
  12. Hill, D.A., Hill, S.R. “Counseling patients about hormone therapy and alternatives for menopausal symptoms.” Am Fam Physician 82 (2010): 801–7.
  13. Tsai, S.A., Stefanick, M.L., Stafford, R.S. “Trends in menopausal hormone therapy use of US office-based physicians, 2000–2009.” Menopause 18 (2011): 385–92.
  14. Kronenberg, F., Cushman, L.F., Wade, C.M., et al. “Race/ethnicity and women`s use of complementary and alternative medicine in the United States: results of national survey.” Am J Public Health 96 (2006): 1236–42.
  15. Reddy, S.Y., Warner, H., Gutusso, T., et al. “Gabapentin, estrogen and placebo for treating hot flashes.” Obstet Gynecol 108 (2006): 41–8.
  16. Fonken, L.K., Randy, J.N. “The effects of light at night on circadian clocks and metabolism.” Endocr Rev 35.4 (2014): 648–70.
  17. Tamura, H., Takasaki, A., Taketani, T., et al. “Melatonin and female reproduction.” J Obstet Gynaecol Res 40 (2014): 1–11.
  18. Hill, S., Belancio, V., Dauchy, R., et al. “Melatonin: an Inhibitor of Breast Cancer.” Endocr Relat Cancer 22 (2015): 183–204.
  19. Tsutsui, K., Ubuka, T., Bentley, G., et al. “Review: regulatory mechanisms of gonadotropin-inhibitory hormone (GnIH) synthesis and release in photoperiodic animals.” Front Neurosci 7 (2013): 60.
  20. Toffol, E., Kallenen, N., Haukka, J., et al. “Melatonin in perimenopausal and postmenopausal women: associations with mood, sleep, climacteric symptoms, and quality of life.” Menopause 21.5 (2014): 493–500.
  21. Anisimov, V.N. “The role of the epiphysis (pineal gland) in the mechanisms of aging.” Successes of gerontology 2 (1998): 74–81.
  22. Grad, B.R., Rozenwaig, R. “The role of melatonin and serotonin in aging.” Psychoneuroendocrinology 18.4 (1993): 283–95.
  23. Slepushkin, V.D., Pashinsky, V.G. Epiphysis and adaptation of the organism. Tomsk. Tomsk University Publishing House (1982): 210 p.
  24. Dolgov, G.V., Tsvelev, Y.V., Malinin, V.V. Bioregulatory therapy in obstetrics and gynecology. St.- Petersburg. “Publishing House Foliant” Ltd (2004): 144 p.
  25. Oosthuizen, G.M., Joubert, G., du Toit, R.S. “A role for melatonin in breast disease and the menopause.” S Afr Med J 91.7 (2001): 576–7.
  26. Rohr, U.D., Herold, J. “Melatonin deficiencies in women.” Maturitas 15.41 Suppl 1 (2002): 85–104.
  27. Rom-Boguslavskaya, E.S. “Epiphysis (pineal gland) in norm and pathology.” Soviet Medicine 8 (1981): 68–73.
  28. Malinovskaya, N.K., Rapoport, S.I. “The role of melatonin in the regulation of gastrointestinal function.” Clinical medicine 8 (1999): 4–9.
  29. Anisimov, V.N. Pineal gland, aging and carcinogenesis. The Pineal Gland and Cancer // D. Gupta, A. Attanasio, R.J. Reiter (Eds.) Brain Research Promotion. London. Tubingen (1988): 107–18.
  30. Garipova, G.H. Clinical significance of melatonin in the course and progression of hyperplastic processes of the endometrium. Thesis abstract for PhD degree. Kazan (2008).
  31. Schwertner, A., Conceição Dos Santos, C.C., Costa, G.D., et al. “Efficacy of melatonin in the treatment of endometriosis: a phase II, randomized, double-blind, placebo-controlled trial.” Pain 154.6 (2013): 874–81.
  32. Acuña-Castroviejo, D., Escames, G., Venegas, C., et al. “Extrapineal melatonin: sources, regulation, and potential functions.” Cell Mol Life Sci 71.16 (2014): 2997–3025.
  33. Cruz, M.H., Leal, C.L., Cruz, J.F., et al. “Essential actions of melatonin in protecting the ovary from oxidative damage.” Theriogenology 82.7 (2014): 925–32.
  34. Fernando, S., Osianlis, T., Vollenhoven, B., et al. “A pilot double-blind randomised placebo-controlled doseresponse trial assessing the effects of melatonin on infertility treatment (MIART): study protocol.” BMJ Open 4.8 (2014): e005986.
  35. Tamura, H., Takasaki, A., Taketani, T., et al. “Melatonin as a free radical scavenger in the ovarian follicle.” Endocr J 60.1 (2013): 1–13.
  36. Connolly, M. “Premenstrual syndrome: an update on definitions, diagnosis and management.” Adv Psyc Treat 7.6 (2001): 469–77.
  37. Diagnostic and Statistical Manual of Mental Disorders, 3rd EditionRevised (1987). Available from: [http:// dsm.psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890420188.dsm-iii-r], last accessed Apr 17, 2017.
  38. Shechter, A., Lespérance, P., Ng Ying Kin, N.M., Boivin, D.B. “Pilot investigation of the circadian plasma melatonin rhythm across the menstrual cycle in a small group of women with premenstrual dysphoric disorder.” PLoS One 7.12 (2012): e51929.
  39. Gafarova, E.A. Clinical significance of melatonin in the development of symptoms of pathological menopause. Thesis abstract for PhD degree. Kazan (2005).
  40. Kolesnikova, L.I., Madaeva, I.M., Semenova, N.V., et al. “Pathogenic role of melatonin in sleep disorders in menopausal women.” Bull Exp Biol Med 156.1 (2013): 104–16.
  41. Vita-melatonin: instruction for use.
  42. de Villiers, T., Tatarchuk, T.F. “National consensus on the management of patients in menopause, Association of gynecologist-endocrinologist of Ukraine, 2015.” Reproductive Endocrinology 1.27 (2016): 8–25.

Downloads

Published

2017-04-30

How to Cite

Яроцкая, Н. В., & Занько, Е. В. (2017). Possibilities of using melatonin in gynecology. REPRODUCTIVE ENDOCRINOLOGY, (34), 96–101. https://doi.org/10.18370/2309-4117.2017.34.96-101

Issue

No. 34 (2017)

Section

Drug therapy

License

Copyright (c) 2017 Н. В. Яроцкая, Е. В. Занько

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.